A Phase 3 interventional study of Dexmedetomidine and Midazolam in Sedation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 37 sites in 2 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2015-08-14.
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine (DEX) in intubated and mechanically ventilated pediatric intensive care unit (PICU) subjects. The key study objectives are:
An estimated 175 subjects will be enrolled at approximately 40 investigative sites. Subjects will be divided into two treatment groups to receive either high dose or low dose Dexmedetomidine (DEX). The loading and maintenance doses in both groups will be stratified according to the presence or absence of cardiopulmonary bypass. The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper); Score 4 (unarousable to stimuli).
Based on these scores and clinical judgment, additional sedation with intravenous midazolam will be administered according to the label. The UMSS scores must be documented before the administration of every midazolam (MDZ) dose and within five minutes after each dose of MDZ. Fentanyl or morphine may be administered to treat pain. Subjects may be extubated after beginning of study drug but are not required to be as part of the study.
The efficacy and safety parameters that will be monitored include sedation levels, heart rate, blood pressure and ventilation indicators. Once subjects have met site-specified respiratory criteria, they will undergo tracheal extubation. The dexmedetomidine infusion may be continued during and after extubation if further sedation is required post-extubation. The continuous infusion of dexmedetomidine must be administered for a minimum of 6 hours and a maximum of 24 hours. Sedation levels, heart rate, blood pressure, respiratory rate, ventilator settings, SpO2 and if available transcutaneous carbon dioxide (TcCO2) and/or arterial blood gases (ABG) will be monitored and recorded in the peri-extubation period.
Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.
First submitted before Hospira became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A dose has been established for this subject's age based upon the diagnosis procedures.
Status post cardiopulmonary bypass (s/p CPB):
All other diagnoses:
If female, subject is non-lactating and is either:
Exclusion Criteria:
Hypotension that persist beyond a 15 min of re-assessments prior to starting study drug:
Pre-existing bradycardia that persists beyond a 15 min period of re-assessment prior to starting study drugs:
Serum glutamic pyruvic transaminase ()/alanine aminotransferase (ALT): 1 month -12 months: >165 U/L; >12 months to \<17 years: ≥100 U/L.
Note: Subjects may be rescreened up to 6 hrs prior to study drug infusion (not including subjects undergoing cardiac surgery with CPB).
Alpha-2 Agonists: Xylazine*, Clonidine (Catapres, Dixarit), Guanfacine (Tenex), Guanabenz (Wytensin), Mivazerol, Guanadrel (Hylorel), Guanethidine (Ismelin) and Methyldopa (Aldomet). * Xylazine is a veterinary product, but has abuse potentIal in humans.
Alpha-2 Antagonists: Corynanthine, Phenoxybenzamine (Dibenzyline), Phentolamine (Regitine, Rogitine), Tolazoline (Priscoline), Yohimbine, Rauwolscine, Idazoxan, Reserpine (Serpasil) and Mirtazapine (Remeron, Remeron Soltab).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl · Drug: Morphine
Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl · Drug: Morphine
Study drug titrated up or down to maintain target UMSS range.
Rescue medication for sedation according to UMSS scores
Rescue medication for pain based on UMSS scores
Rescue medication for pain based on UMSS scores.
Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated.
Clinical Score Level of Sedation 0 Awake/Alert 1. Minimally Sedated: Tired/sleepy, appropriate response to verbal conversation and/or sounds. 2. Moderately Sedated: Somnolent/sleeping, easily aroused with light tactile stimulation. 3. Deeply sedated: Deep sleep, arousable only with significant physical stimulation. 4. Unarousable
Time frame: 6 to 24 hours
Absolute Time on Study Drug That the Subject is in a UMSS Range of 1 to 3 While Intubated
Time frame: 6 to 24 hours
Absolute Time on Study Drug That the Subject is Out of the Target Sedation Range (UMSS <1 or >3) While Intubated
Time frame: 6 to 24 hours
Total Amount of Rescue Medication Required for Sedation and Analgesia While Intubated
Time frame: 6 to 24 hours
Time to First Dose of Rescue Medication for Sedation and Analgesia
Time frame: 6 to 24 hours
Time to Successful Extubation
Time frame: 6 to 24 hours
| Milestone | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Started | 89 | 86 |
| Completed | 77 | 76 |
| Not completed | 12 | 10 |
Clinical Score Level of Sedation 0 Awake/Alert 1. Minimally Sedated: Tired/sleepy, appropriate response to verbal conversation and/or sounds. 2. Moderately Sedated: Somnolent/sleeping, easily aroused with light tactile stimulation. 3. Deeply sedated: Deep sleep, arousable only with significant physical stimulation. 4. Unarousable
| Percentage of subjects | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated. | 44.6 | 54.3 |
| Hours | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Absolute Time on Study Drug That the Subject is in a UMSS Range of 1 to 3 While Intubated | 17.2 (5 to 24) | 17.3 (2 to 24) |
| hours | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Absolute Time on Study Drug That the Subject is Out of the Target Sedation Range (UMSS <1 or >3) While Intubated | 1.0 (0 to 10) | 0.7 (0 to 14) |
| Milligram | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Midazolam | 2.221 ± 4.6089 | 1.241 ± 2.3052 |
| Fentanyl | 45.225 ± 83.7743 | 44.367 ± 112.13 |
| Morphine | 1.446 ± 3.2978 | 1.141 ± 2.4209 |
| Hours | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Time to First Dose of Rescue Medication for Sedation and Analgesia | 1.6 (0.933 to 3.383) | 2.0 (1.067 to 3.750) |
| Hours | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| Time to Successful Extubation | 23.8 (18.550 to NA) | 20.5 (17.133 to 23.333) |
Non-serious events are listed at a 1.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexmedetomidine Low Dose | — | 1/89 (1.1%) | 48/89 (53.9%) |
| Dexmedetomidine High Dose | — | 1/86 (1.2%) | 43/86 (50%) |
| Event | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/89 | 1/86 |
| MyocarditisCardiac disorders | 1/89 | 0/86 |
| Event | Dexmedetomidine Low Dose | Dexmedetomidine High Dose |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 9/89 | 5/86 |
| HypotensionVascular disorders | 4/89 | 7/86 |
| PyrexiaGeneral disorders | 7/89 | 5/86 |
| HypertensionVascular disorders | 7/89 | 0/86 |
| AgitationPsychiatric disorders | 4/89 | 5/86 |
| VomitingGastrointestinal disorders | 2/89 | 4/86 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 3/89 | 4/86 |
| BradycardiaCardiac disorders | 2/89 | 3/86 |
| Oxygen saturation decreasedInvestigations | 1/89 | 3/86 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/89 | 3/86 |
| Age, Continuous(years) | Dexmedetomidine Low Dose | Dexmedetomidine High Dose | Total |
|---|---|---|---|
| Mean | 2.35 ± 3.437 | 2.85 ± 4.172 | 2.60 ± 3.814 |
| Age, Categorical(Participants) | Dexmedetomidine Low Dose | Dexmedetomidine High Dose | Total |
|---|---|---|---|
| <=18 years | 89 | 86 | 175 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Customized(participants) | Dexmedetomidine Low Dose | Dexmedetomidine High Dose | Total |
|---|---|---|---|
| >= 1 month to < 24 months | 63 | 60 | 123 |
| >=24 months to < 17 years old | 26 | 26 | 52 |
| Sex: Female, Male(Participants) | Dexmedetomidine Low Dose | Dexmedetomidine High Dose | Total |
|---|---|---|---|
| Female | 36 | 38 | 74 |
| Male | 53 | 48 | 101 |
| Race (NIH/OMB)(Participants) | Dexmedetomidine Low Dose | Dexmedetomidine High Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 6 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 14 | 14 | 28 |
| White | 64 | 62 | 126 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 7 | 3 | 10 |
| American Society of Anaesthesiologists (ASA) classification(participants) | Dexmedetomidine Low Dose | Dexmedetomidine High Dose | Total |
|---|---|---|---|
| P1 - Normal healthy patient (PT) | 3 | 5 | 8 |
| P2 - PT w/ mild systemic disease | 28 | 16 | 44 |
| P3 - PT w/ severe systemic disease) | 50 | 53 | 103 |
| P4 - PT w/ constant threat to life) | 8 | 12 | 20 |
| P5 - Moribund patient | 0 | 0 | 0 |
| P6 - A declared brain-dead patient | 0 | 0 | 0 |
The record gives a start of Jan 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 3 years 9 months after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Hospira, now a wholly owned subsidiary of Pfizer →